Compare Cipla with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs JUBILANT LIFE SCIENCES - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA JUBILANT LIFE SCIENCES CIPLA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 24.7 15.2 162.0% View Chart
P/BV x 2.5 1.8 141.7% View Chart
Dividend Yield % 0.6 0.8 76.1%  

Financials

 CIPLA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    CIPLA
Mar-19
JUBILANT LIFE SCIENCES
Mar-19
CIPLA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs678898 75.5%   
Low Rs484618 78.3%   
Sales per share (Unadj.) Rs198.2572.0 34.7%  
Earnings per share (Unadj.) Rs18.536.2 51.1%  
Cash flow per share (Unadj.) Rs35.059.5 58.8%  
Dividends per share (Unadj.) Rs3.004.50 66.7%  
Dividend yield (eoy) %0.50.6 87.0%  
Book value per share (Unadj.) Rs186.3301.9 61.7%  
Shares outstanding (eoy) m805.70159.28 505.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.91.3 221.2%   
Avg P/E ratio x31.420.9 149.9%  
P/CF ratio (eoy) x16.612.7 130.4%  
Price / Book Value ratio x3.12.5 124.2%  
Dividend payout %16.212.4 130.4%   
Avg Mkt Cap Rs m468,031120,694 387.8%   
No. of employees `00022.62.4 947.4%   
Total wages/salary Rs m28,56519,260 148.3%   
Avg. sales/employee Rs Th7,053.138,120.6 18.5%   
Avg. wages/employee Rs Th1,261.58,058.4 15.7%   
Avg. net profit/employee Rs Th659.12,414.3 27.3%   
INCOME DATA
Net Sales Rs m159,71091,108 175.3%  
Other income Rs m4,766357 1,333.4%   
Total revenues Rs m164,47591,466 179.8%   
Gross profit Rs m30,97317,390 178.1%  
Depreciation Rs m13,2633,709 357.6%   
Interest Rs m1,6842,198 76.6%   
Profit before tax Rs m20,79111,840 175.6%   
Minority Interest Rs m-1720-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m5,6953,268 174.3%   
Profit after tax Rs m14,9245,770 258.7%  
Gross profit margin %19.419.1 101.6%  
Effective tax rate %27.427.6 99.2%   
Net profit margin %9.36.3 147.6%  
BALANCE SHEET DATA
Current assets Rs m124,26645,848 271.0%   
Current liabilities Rs m37,71520,897 180.5%   
Net working cap to sales %54.227.4 197.9%  
Current ratio x3.32.2 150.2%  
Inventory Days Days9157 159.6%  
Debtors Days Days9551 186.2%  
Net fixed assets Rs m105,19065,498 160.6%   
Share capital Rs m1,611159 1,011.6%   
"Free" reserves Rs m148,51147,930 309.9%   
Net worth Rs m150,12348,089 312.2%   
Long term debt Rs m38,30142,429 90.3%   
Total assets Rs m239,633114,685 208.9%  
Interest coverage x13.36.4 208.9%   
Debt to equity ratio x0.30.9 28.9%  
Sales to assets ratio x0.70.8 83.9%   
Return on assets %6.96.9 99.8%  
Return on equity %9.912.0 82.9%  
Return on capital %11.812.4 95.4%  
Exports to sales %34.70-   
Imports to sales %00-   
Exports (fob) Rs m55,419NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m57,41012,422 462.2%   
Fx outflow Rs m19,04117,227 110.5%   
Net fx Rs m38,368-4,805 -798.5%   
CASH FLOW
From Operations Rs m16,91111,215 150.8%  
From Investments Rs m-16,687-10,118 164.9%  
From Financial Activity Rs m-3,4876,574 -53.0%  
Net Cashflow Rs m-3,4517,612 -45.3%  

Share Holding

Indian Promoters % 16.0 45.6 35.1%  
Foreign collaborators % 20.8 3.5 594.3%  
Indian inst/Mut Fund % 12.2 8.7 140.2%  
FIIs % 23.7 21.2 111.8%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 21.1 124.2%  
Shareholders   161,166 23,815 676.7%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   WOCKHARDT  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON   FULFORD INDIA  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 16, 2019 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS